Research Article: Prognostic value of hemoglobin-to-serum creatinine ratio in patients with coronary artery disease and reduced kidney function following percutaneous coronary intervention
Abstract:
This investigation sought to assess the prognostic significance of the hemoglobin-to-serum creatinine (Hb/SCr) ratio for long-term survival among patients with coexisting coronary artery disease (CAD) and reduced kidney function after percutaneous coronary intervention (PCI).
This retrospective study encompassed 2,310 patients who underwent PCI and had concomitant CAD and reduced kidney function. The cohort median Hb/SCr value of 1.60 was used as a pragmatic reference threshold to classify patients into low (<1.60) and high (?1.60) Hb/SCr groups. The predictive significance of the Hb/SCr ratio regarding cardiac-cause mortality (CCM) and all-cause mortality (ACM) over a follow-up period of up to 60 months was evaluated employing Kaplan–Meier analysis and multivariable Cox proportional hazards models.
During 60 months of follow-up, 56 cardiac-cause deaths (2.4%) and 87 all-cause deaths (3.8%) occurred. Kaplan–Meier analysis showed significantly higher cumulative mortality in the low Hb/SCr group for both CCM (log-rank P =?0.002263) and ACM (log-rank P =?0.002349). The Hb/SCr ratio showed modest discrimination for CCM (AUC 0.663, 95% CI 0.585–0.742) and ACM (AUC 0.614, 95% CI 0.548–0.680). Compared with Hb/SCr?<?1.60, Hb/SCr???1.60 was associated with lower adjusted risks of CCM (HR 0.49, 95% CI 0.27–0.90; P =?0.021) and ACM (HR 0.59, 95% CI 0.37–0.94; P =?0.028). Similar associations were observed when the ratio was analysed as a continuous variable (CCM: HR 0.28, 95% CI 0.14–0.57; ACM: HR 0.42, 95% CI 0.23–0.77).
A lower Hb/SCr ratio independently predicts increased long-term risks of CCM and ACM in patients with CAD and reduced kidney function after PCI. Given its modest discriminative ability, this readily available ratio may serve as a complementary marker for risk stratification rather than a standalone predictive tool, potentially helping to identify patients who warrant closer post-procedural surveillance.
Introduction:
Cardiovascular disease (CVD) continues to represent a primary contributor to global morbidity and mortality, responsible for roughly 20 million deaths each year and imposing substantial strain on healthcare systems worldwide ( 1 , 2 ). Coronary artery disease (CAD) represents the most prevalent type of CVD and remains a major contributor to cardiovascular mortality ( 1 ). Percutaneous coronary intervention (PCI) has become a central therapeutic strategy for CAD and is widely performed to reestablish coronary…
Read more